NCT05351840

To Evaluate the Pharmacokinetic Interactions and Safety in Healthy Volunteers

An Open-label, Multiple-dose, Fixed-sequence, 3-Period Study to Evaluate the Pharmacokinetic Interactions and Safety in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 31 (actual)
• Sponsor: JW Pharmaceutical · Industry
• Sex: All
• Age: 19 Years – 45 Years
• Healthy volunteers: Accepted

Summary

To evaluate and compare the pharmacokinetic interactions and safety of multiple dose of Treatment A and Treatment B alone and in combination

Detailed description

The objective of this study was to evaluate pharmacokinetic characteristics and safety after oral concurrent administration of Treatment A and Treatment B compared to each single administration in Healthy volunteers.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	LivaloV	Treatment A, Tablet, Oral, QD for 7 Days
DRUG	A	Treatment B, Tablet, Oral, QD for 10 Days
DRUG	LivaloVA	Treatment C, Tablet, Oral, QD for 7 Days

Timeline

• Start date: 2020-11-02
• Primary completion: 2020-12-19
• Completion: 2021-01-15
• First posted: 2022-04-28
• Last updated: 2022-08-12

Locations

1 site across 1 country: South Korea